The rapid adoption of GLP-1 medications is doing more than managing weight; it is beginning to rewire consumer behavior and investment priorities across the entire food system. PeakBridge, a leading agrifood venture capital firm and F&A Next organizing partner, is at the forefront of analyzing these shifts to identify where the strongest commercial moats are emerging. Dr. Gali Artzi, CTO and Partner at PeakBridge, argues that while the drugs effectively handle satiety, the most durable commercial opportunities reside in the “food-and-care” layer essential for long-term health outcomes. Here, PeakBridge examines the investment implications of this pharmacological revolution and why nutrition expertise has become a core differentiator for the future of nutrition and care.
What the Headline Numbers Miss
The big numbers on GLP-1 drugs might by now sound familiar: a $157 billion global market by 2035; 25-30 million Americans on treatment; a stunning average weight loss of 15-29% percent of body weight across approved GLP-1 therapies. These are trajectories already in motion, backed by clinical data that has changed the conversation about obesity and turned pharmacology mainstream. But focusing on those impressive statistics risks missing the point. And there are two: what happens on the medication, and what happens after treatment ends.
Over 20% of patients starting GLP-1 therapy are diagnosed with nutritional deficiencies within their first twelve months. Muscle loss comes too. Then there are the acute side effects, notably including nausea, diarrhea and vomiting. Patients enter a new reality that demands real nutritional support and diet and lifestyle management. But only about one in five users currently receives that kind of structured lifestyle support alongside the drugs.
Then there’s what happens after the prescription ends. Most patients come off these drugs within a year, returning to the same food environment they started in after a window of profound appetite suppression. A 2026 meta-regression of 48 studies pegged the trajectory at roughly 60% weight regain within a year, plateauing near 75% over time. A real-world observational study tracking 130 patients for a year after they stopped showed an even sharper picture: 65% regained weight, and nearly half ended up heavier than when they started. Cessation is rarely a clean exit. It’s a transition and one the next wave of digital health and support platforms is being built to address.
The drug does exactly what it was designed to do, but the system around it has not caught up. And that’s one of the biggest commercial opportunities in nutrition for the next decade.
Room to Build
The corporate response to GLP-1 has been visible and, in its own terms, rational. Think Danone and Huel, Unilever and Grüns, Nestlé’s Vital Pursuit launch. Conagra and General Mills reformulating toward higher-protein and portion-controlled lines. Abbott and Premier Protein scaling shake portfolios or Smartfood and Quest leaning hard into satiety positioning. Most of this activity is oriented toward the patient while they are on the drug, because that is where the visible, immediate consumer market sits.
Far less industry attention has gone to what happens after. That asymmetry is, in PeakBridge’s view, one of the bigger open opportunities in the category, and probably an underpriced one, precisely because it does not pattern-match neatly to “food brand.” Cessation from GLP-1 tends to be a phase rather than a single event, and most users will likely move through it more than once over their lifetimes. Whoever builds proactively for that cycle stands to capture a recurring relationship, not a single transaction.
The Long Game Isn’t a Product Play
The most interesting players in the GLP-1 space have realized you can’t play a long game in this space with just a product. The patient journey across onboarding,titration, side effects, adherence, and discontinuation, is likely too long and too variable for a single product to serve well.
Two companies illustrate this from opposite ends of the stack. Noom began as a coaching application and, in 2025, launched Microdose GLP-1Rx: compounded semaglutide at fractions of the standard dose, paired with its existing coaching infrastructure. The logic is direct: over half of those who stop the medication do so because of the cost, and as many as 36% stop because of side effects. Microdosing addresses both. Noom now prescribes, dispenses, doses, and coaches within a single platform. Ilant Health, in the PeakBridge portfolio, approaches the same conclusion from the care-delivery side, building an integrated platform that wraps GLP-1 access inside structured nutrition and clinical support, distributed through employers and payers. Both companies started from very different places and arrived at the same architecture: the relationship across the full patient journey is far more durable and valuable than any single phase of it.
The GLP-1 Investment Thesis: Capturing the Long-Term Nutrition Market
GLP-1 handles satiety it well. But most of what determines long-term outcomes – muscle mass, micronutrient status, sustainable dietary behavior, the off-ramp, the maintenance period, post-cycle rebound – sits entirely in the food-and-care layer. The drug creates a window but does not take care of what happens inside it.
This is where the investment thesis gets interesting, and where expertise in nutrition and food science ceases to be adjacent knowledge and becomes the core differentiating factor. At F&A Next, we’ll dive deeper into exactly that, to break down the real moats for companies in this space, and what investors entering it need to know about a revolution that’s only just getting started.
Dr. Gali Artzi, CTO and Partner at PeakBridge, will explore the investment implications of the GLP-1 revolution at F&A Next 2026.